Black Diamond Therapeutics, Inc. (BDTX)

Name: Black Diamond Therapeutics, Inc. (BDTX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001701541 · Nasdaq · Biological Products, (No Diagnostic Substances)

Sector Manufacturing
Fiscal year ends Dec 31

For the year ended 2025-12-31, Black Diamond Therapeutics, Inc. reported revenue of $70.00M. Over the twelve months to 2026-06-30, revenue was $0.

Key ratios (year ended 2025-12-31)

17.9%

Operating margin

32.0%

Net margin

19.9%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-09-21

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Revenue	$0	$70.00M	$0	n/a	n/a	n/a	n/a	n/a	n/a
R&D Expense	$28.13M	$33.56M	$51.31M	$59.35M	$64.44M	$96.83M	$48.21M	$21.75M	$6.95M
Operating Income	-$51.90M	$12.52M	-$78.78M	-$86.46M	-$92.83M	-$126.87M	-$69.57M	-$29.33M	-$8.90M
Net Income	-$42.55M	$22.37M	-$69.68M	-$82.44M	-$91.17M	-$125.60M	-$67.25M	-$35.26M	-$8.93M
EPS (Diluted)	n/a	$0.39	-$1.27	-$1.88	-$2.52	-$3.47	-$2.05	n/a	n/a
Total Assets	$125.03M	$143.01M	$122.64M	$158.57M	$156.25M	$247.68M	$329.67M	$158.29M	$51.83M
Total Liabilities	$28.94M	$30.80M	$39.35M	$41.83M	$40.56M	$51.78M	$21.91M	$4.88M	$6.60M
Shareholders' Equity	$96.09M	$112.21M	$83.28M	$116.74M	$115.69M	$195.90M	$307.76M	-$47.16M	-$15.54M
Cash & Equivalents	$19.19M	$20.99M	$36.44M	$56.22M	$34.31M	$65.80M	$34.60M	$154.67M	$51.66M
Operating Cash Flow	-$32.84M	$29.61M	-$62.30M	-$66.72M	-$85.08M	-$100.15M	-$52.15M	-$24.67M	-$8.45M
Capital Expenditures	n/a	n/a	$0	$33.0K	$192.0K	$2.71M	$142.0K	$21.0K	$76.0K
Free Cash Flow	n/a	n/a	-$62.30M	-$66.75M	-$85.27M	-$102.86M	-$52.29M	-$24.70M	-$8.53M
Shares Outstanding	57.45M	57.14M	56.64M	51.65M	36.43M	36.23M	36.08M	2.24M	2.17M
Weighted Average Diluted Shares	n/a	57.56M	55.03M	43.95M	36.33M	36.19M	32.91M	n/a	n/a
EPS (Basic)	n/a	$0.39	-$1.27	-$1.88	-$2.52	-$3.47	-$2.05	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView